WAKAYAMA MEDICAL UNIVERSITY

- Country
- ๐ฏ๐ตJapan
- Ownership
- Private
- Established
- 1945-01-01
- Employees
- -
- Market Cap
- -
Isolation Procedure vs. Conventional Procedure During Distal Pancreatectosplenectomy for Pancreatic Cancer
- Conditions
- Resectable Pancreatic Body/Tail Carcinoma
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Wakayama Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT04600063
- Locations
- ๐ฏ๐ต
Kobe University, Kobe, Hyogo, Japan
๐ฏ๐ตNara Medical University, Kashihara, Nara, Japan
๐ฏ๐ตKinki University, Sayama, Osaka, Japan
Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer
- Conditions
- Pancreatic Ductal AdenocarcinomaMesenteric ApproachPancreaticoduodenectomy
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Wakayama Medical University
- Target Recruit Count
- 354
- Registration Number
- NCT03317886
- Locations
- ๐ฏ๐ต
Kyusyu University, Fukuoka, Japan
๐ฏ๐ตKansai Medical University, Hirakata, Japan
๐ฏ๐ตHiroshima University, Hiroshima, Japan
Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Wakayama Medical University
- Target Recruit Count
- 25
- Registration Number
- NCT03253068
- Locations
- ๐ฏ๐ต
Wakayama Medical University, Wakayama, Japan
Study of NAC of GA Therapy for Patients With BRPC
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2019-10-03
- Lead Sponsor
- Wakayama Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT02926183
- Locations
- ๐ฏ๐ต
Hirosaki University, Hirosaki, Aomori, Japan
๐ฏ๐ตKobe University, Kobe, Hyogo, Japan
๐ฏ๐ตHyogo College of Medicine, Nishinomiya, Hyogo, Japan
Combined Resection vs. Separated Resection After Mobilization of Splenic Vein During Distal Pancreatectomy
- Conditions
- Pancreatic Neoplasms
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Wakayama Medical University
- Target Recruit Count
- 304
- Registration Number
- NCT02871804
- Locations
- ๐ฏ๐ต
Wakayama Medical University, Wakayama, Japan
The Prediction Using Diffusion MRI of the Response Evaluation in BRPC in NAT.
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- Wakayama Medical University
- Target Recruit Count
- 28
- Registration Number
- NCT02777463
- Locations
- ๐ฏ๐ต
Wakayama Medical University, Wakayama, Wakayama Prefecture, Japan
Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer.
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: NAC-GEMABR
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Wakayama Medical University
- Target Recruit Count
- 10
- Registration Number
- NCT02506803
- Locations
- ๐ฏ๐ต
Wakayama Medical University, Wakayama, Japan
Predictive Risk Factors for Pancreatic Fistula Grade C After Pancreaticoduodenectomy
- Conditions
- Disease of Pancreatic Head or Periampullary Lesions to Require Pancreaticoduodenectomy
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Wakayama Medical University
- Target Recruit Count
- 3000
- Registration Number
- NCT02322424
- Locations
- ๐จ๐ณ
Chang Gun Memorial Hospital, Linkou, Taiwan
A Prospective, Multi-center Trial for Reinforced Staple During Distal Pancreatectomy
- Conditions
- Pancreatic Neoplasms
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Wakayama Medical University
- Target Recruit Count
- 120
- Registration Number
- NCT02270554
- Locations
- ๐ฏ๐ต
Kansai Rosai Hospital, Amagasaki, Hyogo, Japan
๐ฏ๐ตKansai Medical University, Hirakata, Osaka, Japan
๐ฏ๐ตHiroshima University, Hiroshima, Hiroshima, Japan
Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study
- Conditions
- Patients With Borderline Resectable Pancreatic Cancer
- Interventions
- Drug: FIRINOX
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- Wakayama Medical University
- Target Recruit Count
- 10
- Registration Number
- NCT02148549
- Locations
- ๐ฏ๐ต
Nagoya University, Nagoya, Aichi, Japan
๐ฏ๐ตKobe University, Kobe, Hyogo, Japan
๐ฏ๐ตNara Prefectual Medical University, Kashihara, Nara, Japan